Primum non nocere: do we harm stage I testicular cancer patients less by applying adjuvant chemotherapy than by failing to present this option?
Department of Oncology, Akershus University Hospital, Norway and University of Oslo, Lørenskog, Norway jan.oldenburg@medisin.uio.no.
J
J
Oldenburg
Department of Medical Oncology, Queen Elizabeth Hospital, University Hospital Birmingham Foundation Trust, Birmingham, UK.
M
M
Cullen
The Cancer Clinic, St Olavs University Hospital, Trondheim, Norway.
T
T
Tandstad
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002945:Cisplatin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D018570:Risk Assessment; D013736:Testicular Neoplasms / Q000188:drug therapy*
D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin